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Pregnancy outcomes in Liberian women who conceived after 
recovery from Ebola virus disease 
Although sporadic outbreaks continue to arise in west 
Africa, the recent Ebola virus disease (EVD) epidemic, 
which resulted in nearly 28 650 cases, has been 
contained. In Liberia speciﬁ cally, the epidemic began in 
June, 2014, with the latest outbreak ending in January, 
2016. Over 10 670 probable, suspected, and conﬁ rmed 
cases have been documented to date in the country.1 
Individuals who survived EVD now face signiﬁ cant 
health challenges.2 Post-Ebola syndrome has been 
associated with uveitis, headache and other neurological 
symptoms, musculoskeletal pain, and insomnia, at 
least some of which are suspected to involve viral 
sequestration in body tissues and ﬂ uids.3 The medical 
issues of EVD survivors are often compounded by social 
stigmatisation due to fears of viral reactivation and 
potential transmission. Although pregnancy during 
acute EVD has been almost invariably associated with 
fetal loss,4,5 little is understood as to the antenatal 
courses and pregnancy outcomes in female EVD 
survivors who conceived after recovery.  
We collated demographic and treatment history data 
on women who recovered from EVD and sought health 
care for pregnancy between October, 2014, and April, 
2016, at designated referral facilities (JFK Hospital, 
ELWA Hospital, Redemption Hospital, or Duport Road 
Health Center in Montserrado County; Dolo Town 
Health Center, Hindi Clinic, Worhn Clinic or C H Rennie in 
Margibi County). Approval for data collection was via the 
Ministry of Health (MOH) Incident Management System 
for overseeing the Liberian response to Ebola. History 
of conﬁ rmed EVD was veriﬁ ed using the oﬃ  cial MOH 
database. Maternal age, number of months between 
discharge from an Ebola treatment unit and conception, 
frequency of antenatal care, and pregnancy outcomes 
were analysed. There were no exclusion criteria.
70 EVD pregnant survivors from Montserrado (n=54) 
and Margibi (n=16) counties were evaluated as of 
April 28, 2016. Of these, 15 women miscarried (six in 
Montserrado, nine in Margibi); four neonates were 
stillborn (deﬁ ned as fetal death ≥28 weeks’ gestation; 
three in in Montserrado, one in Margibi); and two EVD 
survivors elected to terminate their pregnancies (both in 
Montserrado). Mean age and number of antenatal care 
visits per month of pregnancy were not signiﬁ cantly 
diﬀ erent between the group of 49 whose pregnancies 
resulted in normal births and the 19 women who 
experienced stillbirth or miscarriage (26·4 years [SD 5·7] 
vs 28·8 years [6·8], and 0·78 visits [0·24] vs 0·72 visits 
[0·40], respectively). In seven cases, the mothers’ 
partners were also EVD survivors; six of the seven had 
apparently normal infants and one had a miscarriage.
Notably, of six pregnancies that occurred within 
2 months of discharge from the Ebola treatment unit, 
three resulted in stillbirths (ﬁ gure 1). One additional 
stillbirth occurred in a pregnancy conceived 6 months 
after recovery. In contrast, all 15 miscarriages occurred 
in women who became pregnant 4 months or longer 
after discharge (ﬁ gure 1). The mean interval in months 
between recovery from acute EVD and conception 
was signiﬁ cantly shorter in women who had stillbirths 
than in those who had miscarriages (mean 2·5 months 
[SD 2·4] vs 9·9 months [3·0] ; p=0·0011). 
The overall miscarriage rate in clinically identiﬁ ed 
pregnancies for this cohort of Ebola survivors (15/68; 
22·1%) was slightly higher than the ranges expected for 
healthy women in developed countries (10–15%)6 and 
women in west Africa (11–13%),7 although published 
data on miscarriages are sparse. Taken together, the 
rate of adverse pregnancy outcomes in the present 
cohort (19/68; 27·9%) suggests the possibility that 
EVD engendered reproductive health risks after clinical 
Figure 1: Frequency of adverse pregnancy outcomes relative to the interval 
(months) between discharge from the Ebola treatment unit (ETU) and 
conception
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disease resolved, especially when pregnancy occurred 
within 2 months of recovery. Prospective evaluation 
of additional pregnancy outcomes in EVD survivors 
compared to age-matched controls from west Africa 
will be helpful to further quantify the relative risks of 
adverse pregnancy outcomes.
We disclose a number of caveats to the interpretation 
of these ﬁ ndings. Liberia-speciﬁ c miscarriage rates 
among uninfected women before, during, or after the 
acute epidemic were not available. EVD survivors who 
noted or suspected problems with their pregnancy 
may have been more likely to seek medical attention 
than those who did not. Indeed, the vast diﬀ erence in 
miscarriage frequencies between Margibi (9/16; 56·3%) 
and Montserrado (6/52; 11·5%) counties suggests 
a possible case-ﬁ nding artifact; we are unaware of a 
biologically plausible explanation. Conversely, it is 
conceivable that our ﬁ ndings underestimate the number 
of stillbirths and miscarriages among EVD survivors; for 
example, under-reporting may have occurred due to fear 
of stigmatisation or because of disrupted health services 
in the aftermath of the Ebola outbreak.
It has been postulated that Ebola virus persistence 
in immune-privileged sites such as brain and retina 
may pose risks to the developing fetus of the gravid 
EVD survivor.8 Male survivors have been shown to shed 
Ebola virus RNA in semen for at least 18 months after 
onset of EVD.9 There has been one report of Ebola virus 
relapse in the central nervous system of a 39-year-
old female EVD survivor.10 Evidence of Ebola virus 
persistence in other female survivors of childbearing age 
would heighten the concerns raised here. If conﬁ rmed, 
potential mechanistic questions include whether the 
reduced immune response during pregnancy and the 
immunological functions of the placenta, which allow 
fetus and mother to co-exist, may increase risk of 
reactivation, and whether genetic risk factors play a role.
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